Business Description
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Business History
Price History (1 Year)
Key Metrics
EPS (Diluted): N/A
Total Equity: N/A
Shares: N/A
Total Debt: $0.00
Cash: $0.00
EBITDA: N/A
Total Debt: $0.00
Cash: $0.00
Revenue: N/A
Shares: N/A
Revenue: N/A
Revenue: N/A
Revenue: N/A
Total Equity: N/A
Tax Rate: N/A
Equity: N/A
Total Debt: $0.00
Cash: $0.00
Current Liabilities: N/A
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: N/A
Shares: N/A
Shares: N/A
CapEx: $0.00
Shares: N/A
Stock Price: $14.01
Net Income: N/A
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement
Requires paid FMP plan for this ticker
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 12:53am (9h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$76.1M $64.0M – $88.3M
|
$731.7M $600.5M – $863.0M
|
$2.0B $1.6B – $2.3B
|
$3.9B $3.2B – $4.6B
|
| EBITDA |
$15.2M $12.8M – $17.7M
|
$146.3M $120.1M – $172.6M
|
$395.7M $324.7M – $466.7M
|
$785.1M $644.3M – $925.9M
|
| Net Income |
-$898.7M -$996.5M – -$738.9M
|
-$438.3M -$742.1M – $207.1M
|
$243.3M $186.5M – $300.0M
|
$1.3B $984.1M – $1.6B
|
| EPS | — | — | — | — |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:05am (1h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Zanganeh Mahkam | P-Purchase | 3,810,000.00 | $13.12 | $50.0M |
| 2026-06-12 | DUGGAN ROBERT W | P-Purchase | 3,810,000.00 | $13.12 | $50.0M |
| 2026-06-04 | DUGGAN ROBERT W | P-Purchase | 100,000.00 | $14.60 | $1.5M |
| 2026-06-04 | Zanganeh Mahkam | P-Purchase | 100,000.00 | $14.60 | $1.5M |
| 2026-06-04 | Soni Manmeet Singh | P-Purchase | 25,000.00 | $14.43 | $360,750 |
| 2026-06-04 | Soni Manmeet Singh | P-Purchase | 25,000.00 | $14.46 | $361,500 |
| 2026-01-08 | Anand Bhaskar | A-Award | 30,000.00 | $18.83 | $564,900 |
| 2026-01-02 | Zanganeh Mahkam | A-Award | 11,232.00 | $17.52 | $196,785 |
| 2026-01-02 | DUGGAN ROBERT W | A-Award | 11,232.00 | $17.52 | $196,785 |
| 2026-01-02 | Booth Robert F. | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Booth Robert F. | A-Award | 7,180.00 | $17.52 | $125,794 |
| 2026-01-02 | Xia Yu | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Huber Jeff | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Huber Jeff | A-Award | 9,885.00 | $17.52 | $173,185 |
| 2026-01-02 | Ronaghi Mostafa | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Clark Kenneth A | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Clark Kenneth A | A-Award | 17,796.00 | $17.52 | $311,786 |
| 2026-01-02 | Cesano Alessandra | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Cesano Alessandra | A-Award | 3,219.00 | $17.52 | $56,397 |
| 2025-10-21 | Xia Yu | P-Purchase | 533,617.00 | $18.74 | $10.0M |
Narrative Economics
market-narrative step).